Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019

Written by Customer Service on . Posted in Public Companies.


This is an unofficial in-house translation of the Swedish original. In case of differences the
Swedish version shall prevail.Oasmia Pharmaceutical AB (publ) held an Extraordinary General Meeting during Wednesday, November 6, 2019. In accordance with the Board’s proposal, the EGM resolved that the Board may, on one or more occasions, decide to issue new shares, within the limits of the Articles of Association, with preferential rights for existing shareholders to be paid in cash, by non-cash consideration and / or through set-off, until the next Annual General Meeting.The purpose of the authorization is for the proceeds of the rights issue to be used mainly to finance and accelerate the commercialization of Apealea and capture new business opportunities based on the Company’s unique XR17 platform. In addition, Oasmia intends to create a stable financial position for the Company that enables expansion in new areas and a stable flow of new projects.Issuance of new shares under the authorization shall be carried out under customary conditions under prevailing market conditions. The Board has the right to decide on new issues of up to a total amount of approximately SEK 400 million with the support of the authorization.The Board, or the person appointed by the Board, shall be given the right to make the minor adjustments to the above decisions which may prove necessary in connection with registration with the Swedish Companies Registration Office.It is noted that the issue authorization that was approved at the Annual General Meeting on September 26, 2019 applies in addition to the above issue authorization, regardless of whether the above authorization applies or not.For more information:
Urban Ekelund, Head of Investor Relations Oasmia
E-mail: IR@oasmia.comAbout Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq Stockholm (OASM) and Frankfurt Stock Exchange (OMAX.GR).AttachmentKommuniké EGM Oasmia 6 nov ENG FINAL

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.